prucalopride (Resotran, Motegrity)
Jump to navigation
Jump to search
Indications
Contraindications
- Crohn's disease
- ulcerative colitis
- toxic megacolon/megarectum
Dosage
Adverse effects
- headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, fatigue[2]
- depression, reports of suicidal ideation (monitor)
- uncharacterized (on list of drugs to avoid)[1]
Mechanism of action
- 5-HT4 receptor agonist
- stimilates colonic peristalsis
More general terms
References
- ↑ 1.0 1.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/
- ↑ 2.0 2.1 Brooks M FDA OKs Prucalopride (Motegrity) for Chronic Idiopathic Constipation. Medscape - Dec 18, 2018. https://www.medscape.com/viewarticle/906732
- ↑ 3.0 3.1 Musa A, Geimadi A, Georgis MT et al Ogilvie Syndrome (Acute Colonic Pseudo-obstruction): Early Recognition and Treatment Are Key. Medscape. Nov 18, 2022 https://reference.medscape.com/slideshow/ogilvie-syndrome-6014904